Recent Company News

• 04:30 PM ET Mar 23, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:45 AM ET Aug 19, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:34 AM ET Aug 19, 2026
  

  Mereo BioPharma Group downgraded to underweight from neutral at JPMorgan ($0.31, 0.00)

• 02:03 PM ET Aug 17, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 10-Aug

• 09:18 AM ET Aug 11, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:18 AM ET Aug 11, 2026
  

  Mereo BioPharma Group reports Q2 EPS ($0.01) vs FactSet ($0.01) [5 est, ($0.01)-0.00] ($0.27, 0.00)

• 08:04 AM ET Aug 11, 2026
  

  Sentynl Therapeutics and Mereo BioPharma announce option and license agreement for alvelestat in AATD-LD ($0.27, 0.00)

• 11:23 AM ET Jun 04, 2026
  

  Transcript Intelligence: Mereo BioPharma Group at Jefferies Global Healthcare Conference ($0.33, 0.00)

• 07:33 AM ET May 12, 2026
  

  Mereo BioPharma Group reports Q1 EPS ($0.01) vs FactSet ($0.01) [6 est, ($0.05)-0.04] ($0.24, 0.00)